SLDB: Advancing gene therapies for DMD and FA with novel delivery, key FDA meetings, and strong cash runway
The company is advancing gene therapies for Duchenne muscular dystrophy and Friedreich's ataxia, with key FDA meetings and data readouts expected in the next two quarters. Novel delivery platforms and simplified immunosuppression protocols differentiate their programs, and a strong cash position su…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.